### SAFETY DATA SHEET



TEKNOCOAT AQUA 2575-33 - NCS S 0502-Y

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : TEKNOCOAT AQUA 2575-33 - NCS S 0502-Y

1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

responsible for this SDS

**National contact** 

Teknos (UK) Limited, 7 Longlands Rd, Bicester, Oxfordshire OX26 5AH, United Kingdom. Tel. +44 (0) 1869 208005.

1.4 Emergency telephone number

National advisory body/Poison Centre
Telephone number : NHS: 111

#### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

<u>Classification according to UK CLP/GHS</u>

Skin Sens. 1, H317

The product is classified as hazardous according to UK CLP Regulation SI 2019/720 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms



Signal word : Warning

**Hazard statements** : H317 - May cause an allergic skin reaction.

**Precautionary statements** 

**Prevention**: P280 - Wear protective gloves.

P261 - Avoid breathing vapour.

**Response** : P362 + P364 - Take off contaminated clothing and wash it before reuse.

P302 + P352 - IF ON SKIN: Wash with plenty of water.

P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention.

Storage : Not applicable.

Disposal : P501 - Dispose of contents and container in accordance with all local, regional,

national and international regulations.

Supplemental label

elements

: Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist. Contains biocidal products for in-can preservation: BIT and C

**Label No** : **7**4790

(M)IT/MIT (3:1) and MIT and DTBMA and Bronopol and OIT and MBIT.

Date of issue/Date of revision : 01/12/2023 Date of previous issue : 19/09/2022 Version : 1.01 1/18

### **SECTION 2: Hazards identification**

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

: Not applicable.

#### 2.3 Other hazards

**Product meets the criteria** for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

vPvB.

Other hazards which do not result in classification : None known.

### **SECTION 3: Composition/information on ingredients**

#### : Mixture 3.2 Mixtures

Product/ingredient name	Identifiers	%	Classification	Type
itanium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≥10 - ≤25	Carc. 2, H351 (inhalation)	[1] [*]
2,4,7,9-tetramethyl-5-decyne- 4,7-diol	REACH #: 01-2119954390-39 EC: 204-809-1 CAS: 126-86-3	<1	Eye Dam. 1, H318 Skin Sens. 1B, H317 Aquatic Chronic 3, H412	[1]
Dipropyleneglycolmethylether	REACH #: 01-2119450011-60 EC: 252-104-2 CAS: 34590-94-8	≤1	Not classified.	[2]
adipohydrazide	REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8	≤0.3	Skin Sens. 1, H317 Aquatic Chronic 2, H411	[1]
Ethanediol	REACH #: 01-2119456816-28 EC: 203-473-3 CAS: 107-21-1 Index: 603-027-00-1	≤0.3	Acute Tox. 4, H302 STOT RE 2, H373 (oral)	[1] [2]
2-Butoxyethanol	REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0	≤0.1	Acute Tox. 4, H302 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319	[1] [2]
Ammonia	REACH #: 01-2119488876-14 EC: 215-647-6 CAS: 1336-21-6 Index: 007-001-01-2	<0.1	Skin Corr. 1B, H314 Eye Dam. 1, H318 STOT SE 3, H335 Aquatic Acute 1, H400 (M=1)	[1] [2]
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)	CAS: 55965-84-9 Index: 613-167-00-5	<0.0025	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 (M=100) Aquatic Chronic 1, H410 (M=100) EUH071	[1]
2-methyl-2H-isothiazol-3-one	EC: 220-239-6 CAS: 2682-20-4	<0.01	Acute Tox. 3, H301 Acute Tox. 3, H311	[1]

: 01/12/2023 : 19/09/2022 Version : 1.01 2/18 Date of issue/Date of revision Date of previous issue **Label No** : **7**4790

<b>SECTION 3: Comp</b>	osition/information on i	ngredients		
			Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 1, H410 (M=1) EUH071	
2-aminoethanol	EC: 205-483-3 CAS: 141-43-5 Index: 603-030-00-8	≤0.1		[1] [2]
Propylene glycol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	≤0.1	Not classified.	[2]
Dibutyltindilaurate	REACH #: 01-2119496068-27 EC: 201-039-8 CAS: 77-58-7	<0.1	Eye Dam. 1, H318 Skin Sens. 1, H317 Muta. 2, H341 Repr. 1B, H360 STOT SE 1, H370 STOT RE 1, H372 Aquatic Acute 1, H400 (M=1) Aquatic Chronic 1, H410 (M=1) See Section 16 for the full text of the H	[1] [2]
			statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

#### Type

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter ≤ 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

#### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

**Eye contact** 

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

**Skin contact** 

: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Date of issue/Date of revision : 01/12/2023 Date of previous issue · 19/09/2022 Version : 1.01 3/18 **Label No** : **7**4790

#### **SECTION 4: First aid measures**

#### Ingestion

: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

#### **Protection of first-aiders**

: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

#### 4.2 Most important symptoms and effects, both acute and delayed

#### Over-exposure signs/symptoms

Eye contact : No specific data.

Inhalation : No specific data.

**Skin contact**: Adverse symptoms may include the following:

irritation redness

Ingestion : No specific data.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

**Specific treatments**: No specific treatment.

### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing

: None known.

media

### 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture

: In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous combustion products

: Decomposition products may include the following materials: carbon dioxide

carbon monoxide metal oxide/oxides

#### 5.3 Advice for firefighters

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Label No** : **7**4790

Special protective equipment for fire-fighters

 Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Date of issue/Date of revision : 01/12/2023 Date of previous issue :19/09/2022 Version :1.01 4/18

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

#### For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

#### 6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

#### 6.3 Methods and material for containment and cleaning up

#### **Small spill**

: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

#### Large spill

: Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

#### 6.4 Reference to other sections

: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

### SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

#### **Protective measures**

: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

### Advice on general occupational hygiene

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

#### 7.3 Specific end use(s)

Recommendations : Not available.

Date of issue/Date of revision : 01/12/2023 Date of previous issue · 19/09/2022 Version : 1.01 5/18 **Label No** : **7**4790

### SECTION 7: Handling and storage

**Industrial sector specific** 

: Not available.

solutions

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

Occupational exposure limits

**D**ipropyleneglycolmethylether EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed

through skin.

TWA: 308 mg/m<sup>3</sup> 8 hours. TWA: 50 ppm 8 hours.

Ethanediol EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed

through skin.

TWA: 10 mg/m<sup>3</sup> 8 hours. Form: Particulate TWA: 20 ppm 8 hours. Form: Vapour STEL: 40 ppm 15 minutes. Form: Vapour TWA: 52 mg/m<sup>3</sup> 8 hours. Form: Vapour STEL: 104 mg/m<sup>3</sup> 15 minutes. Form: Vapour

EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed 2-Butoxyethanol

through skin.

STEL: 50 ppm 15 minutes. TWA: 25 ppm 8 hours. STEL: 246 mg/m<sup>3</sup> 15 minutes. TWA: 123 mg/m<sup>3</sup> 8 hours.

Ammonia EH40/2005 WELs (United Kingdom (UK), 1/2020). [ammonia

anhydrous]

STEL: 25 mg/m3 15 minutes. Form: anhydrous STEL: 35 ppm 15 minutes. Form: anhydrous TWA: 25 ppm 8 hours. Form: anhydrous TWA: 18 mg/m<sup>3</sup> 8 hours. Form: anhydrous

2-aminoethanol EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed

through skin.

STEL: 7.6 mg/m<sup>3</sup> 15 minutes. STEL: 3 ppm 15 minutes. TWA: 1 ppm 8 hours. TWA: 2.5 mg/m<sup>3</sup> 8 hours.

EH40/2005 WELs (United Kingdom (UK), 1/2020). Propylene glycol

TWA: 10 mg/m<sup>3</sup> 8 hours. Form: Particulate

TWA: 474 mg/m<sup>3</sup> 8 hours. Form: total vapour and particulates TWA: 150 ppm 8 hours. Form: total vapour and particulates EH40/2005 WELs (United Kingdom (UK), 1/2020). [tin

compounds, organic, except cyhexatin (ISO) as Sn] Absorbed

through skin.

STEL: 0.2 mg/m³, (as Sn) 15 minutes. TWA: 0.1 mg/m³, (as Sn) 8 hours.

#### **Biological exposure indices**

Dibutyltindilaurate

Product/ingredient name	Exposure indices
Z-Butoxyethanol	EH40/2005 BMGVs (United Kingdom (UK), 8/2018) BGV: 240 mmol/mol creatinine, butoxyacetic acid [in urine]. Sampling time: post shift.

**Recommended monitoring** procedures

Reference should be made to appropriate monitoring standards. Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

Date of issue/Date of revision : 01/12/2023 Date of previous issue · 19/09/2022 Version : 1.01 6/18 **Label No** : **7**4790

# SECTION 8: Exposure controls/personal protection

Product/ingredient name	Туре	Exposure	Value	Population	Effects
2,4,7,9-tetramethyl-5-decyne-4,7-diol	DNEL	Long term Oral	0.25 mg/	General	Systemic
			kg bw/day	population	
	DNEL	Long term Dermal	0.25 mg/	General	Systemic
	DNE	1 4	kg bw/day	population	0
	DNEL	Long term Inhalation	0.43 mg/m <sup>3</sup>	General population	Systemic
	DNEL	Long term Dermal	0.5 mg/kg	Workers	Systemic
	DIVLL	Long term Berman	bw/day	VVOINGIO	Cyclenno
	DNEL	Short term Oral	0.75 mg/	General	Systemic
			kg bw/day	population	
	DNEL	Short term Dermal	0.75 mg/	General	Systemic
	5.151		kg bw/day	population	
	DNEL	Short term Inhalation	1.29 mg/m <sup>3</sup>	General	Systemic
	DNEL	Short term Dermal	1.5 mg/kg	population Workers	Systemic
	DIVLL	Onort term Dermai	bw/day	VVOINCIS	Oysterine
	DNEL	Long term	1.76 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation	Ü		,
	DNEL	Short term	5.28 mg/m <sup>3</sup>	Workers	Systemic
5	5.151	Inhalation			
Dipropyleneglycolmethylether	DNEL	Long term Oral	36 mg/kg	General	Systemic
	DNEL	Long term	bw/day 37.2 mg/m³	population General	Systemic
	DINEL	Inhalation	Jr.Z mg/m	population	Оузісініс
	DNEL	Long term Dermal	121 mg/kg	General	Systemic
		J	bw/day	population	,
	DNEL	Long term Dermal	283 mg/kg	Workers	Systemic
			bw/day		
	DNEL	Long term	308 mg/m <sup>3</sup>	Workers	Systemic
adinahudrazida	DNEL	Inhalation	17 E ma/m³	Morkoro	Cuatamia
adipohydrazide	DINEL	Long term Inhalation	17.5 mg/m³	vvorkers	Systemic
Ethanediol	DNEL	Long term	7 mg/m³	General	Local
		Inhalation	<b>g</b>	population	
	DNEL	Long term	35 mg/m³	Workers	Local
		Inhalation			
	DNEL	Long term Dermal	53 mg/kg	General	Systemic
	DNEL	Long term Dermal	bw/day 106 mg/kg	population Workers	Systemic
	DINEL	Long term Dermai	bw/day	VVOIKEIS	Systemic
2-Butoxyethanol	DNEL	Long term Oral	6.3 mg/kg	General	Systemic
			bw/day	population	*
	DNEL	Short term Oral	26.7 mg/	General	Systemic
	D	1	kg bw/day	population	0
	DNEL	Long term Inhalation	59 mg/m <sup>3</sup>	General	Systemic
	DNEL	Long term	98 mg/m³	population Workers	Systemic
	DI NEL	Inhalation	Jo mg/m	TTORKOIS	Эускоппо
	DNEL	Short term	147 mg/m³	General	Local
		Inhalation		population	
	DNEL	Short term	246 mg/m <sup>3</sup>	Workers	Local
	ראבי	Inhalation	106	Conord	Cyptorsis
	DNEL	Short term Inhalation	426 mg/m <sup>3</sup>	General population	Systemic
	DNEL	Short term	1091 mg/	Workers	Systemic
	,	Inhalation	m <sup>3</sup>		_ ,
reaction mass of: 5-chloro-2-methyl-	DNEL	Long term	0.02 mg/m <sup>3</sup>		Local
4-isothiazolin-3-one [EC no.		Inhalation		population	
247-500-7] and 2-methyl-2H-					
isothiazol-3-one [EC no. 220-239-6]					
(3:1)	DNEL	Long term	0.02 mg/m <sup>3</sup>	Workers	Local
	DINCL	Inhalation	0.02 mg/m²	VVUINCIS	LUCAI
	DNEL	Short term	0.04 mg/m <sup>3</sup>	General	Local
			9		

Date of issue/Date of revision

: 01/12/2023 Date of previous issue

: 19/09/2022

**Version** : 1.01 **7/18** 

**TEKNOCOAT AQUA 2575-33 - NCS S 0502-Y** 

**Label No** :**7**4790

# SECTION 8: Exposure controls/personal protection

Inhalation   DNEL   Short term oral   Long term   DNEL   Long term		•	•	•		
Inhalation   DNEL   Long term (rat   Morkers   Doublation   DNEL   Long term (rat   Morkers   Doublation   DNEL   Long term (rat   Morkers   Doublation   DNEL   Long term (rat   DNEL   Long term (			Inhalation		population	
Inhalation   DNEL   Long term (rat   Morkers   Doublation   DNEL   Long term (rat   Morkers   Doublation   DNEL   Long term (rat   Morkers   Doublation   DNEL   Long term (rat   DNEL   Long term (		DNEL	Short term	0.04 mg/m <sup>3</sup>	Workers	Local
DNEL   Long term Oral   Now widey   O.021 mg/ kg bw/day   O.023 mg/ kg bw/day   O.023 mg/ kg bw/day   O.023 mg/ kg bw/day   O.024						
DNEL Short term Oral DNEL Long term Inhalation DNEL DNEL Short term Dermal DNEL Long term Dermal DNEL Long term DNEL Short term Dermal DNEL Long term DNEL Long term DNEL Short term DNEL DNEL Long term DNEL DNEL DNEL DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DNEI		0.00 mg/	Conoral	Systemia
2-methyl-2H-isothiazol-3-one  DNEL Long term inhalation DNEL Long term oral Short term oral Short term oral Short term oral Short term oral Long term oral Long term oral Long term oral Long term oral Short term oral Short term oral Long term oral		DINEL	Long term Oral	•		Systemic
DNEL   Long term   Inhalation   DNEL   Long term   Inhalatio						
2-methyl-2H-isothiazol-3-one		DNEL	Short term Oral	0.11 mg/	General	Systemic
2-methyl-2H-isothiazol-3-one				kg bw/dav	population	
Inhalation	2-methyl-2H-isothiazol-3-one	DNFI	Long term			Local
DNEL   Long term   0.021 mg/   Workers   Local   maintain   Long term   0.027 mg/   General   population   Local	2 mounty 211 looking2of o one	DIVEL				Local
Inhalation		D. 151				
DNEL		DNEL			Workers	Local
DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dremal DNEL Long term Inhalation DNEL Short term Dermal DNEL Dnet term Dremal DNEL			Inhalation	m³		
DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dremal DNEL Long term Inhalation DNEL Short term Dermal DNEL Dnet term Dremal DNEL		DNEL	Long term Oral	0.027 ma/	General	Systemic
DNEL   Short term   0.043 mg/   population   DNEL   Cocal     DNEL   Cong term   Inhalation   DNEL   Long term   DNEL   Short term Dermal   DNEL   Short term   DNED   DNEL   Short term   DNED   DNEL   Long term   Inhalation   DNEL   Short term   DNED   DNEL   Short term   DNED   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   DRIMAL   DNEL   Long term   DNED   DNEL   Short term   DRIMAL   DNEL   Long term   DNED			3		nonulation	,
Inhalation   DNEL   Short term   DNEL   Long term   Inhalation   DNEL   Short term   Dermal   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   DNEL   Short term   Dermal   DNEL   Short term   Dermal   DNEL   Long term   Dermal   DNEL   Long term   Dermal   DNEL   Long term   Dermal   DNEL   Long term   DRATION		DNEI	Short torm			Local
DNEL Inhalation DNEL Long term Inhalation DNEL Long term Doublation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL DNEL Short term Dnemal DNEL Short term Dnemal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DINEL				Local
Inhalation   Short term Oral   O.053 mg/ kg bw/day   O.18 mg/m3   General population   Systemic population						
2-aminoethanol  DNEL   Long term   Long term   Inhalation   DNEL   Long term   Inhalation   Inhalation   DNEL   Long term   Inhalation   Inha		DNEL	Short term	0.043 mg/	Workers	Local
2-aminoethanol  DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL Long term DNEL Long term Inhalation DNEL Long term DNEL Long term Inhalation DNEL Long term DNEL Short term DNEL Long term DNEL Short term DNEL Long term DNEL DNEL DNEL Long term DNEL DNEL DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL			Inhalation	m³		
2-aminoethanol  DNEL Long term Inhalation Long term Inhalation DNEL Short term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DNFI	Short term Oral	0.053 mg/	General	Systemic
DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term   Demal   DNEMWorkers   Systemic   Syst			2			- , = , =
Inhalation   Long term   Inhalation   DNEL   Short term   Douglation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Douglation   DNEL   Long term   Inhalation   DNEL   Long term   Douglation   Systemic   Douglation   Douglation   Systemic   Douglation   Systemic   Douglation   Systemic   Douglation   Systemic   Systemic   Douglation   Systemic   Systemic   Systemic   Douglation   Systemic   Systemic   Douglation   Systemic   S	2 amain a ath a na l	חאורי	l amartamas			Cuetamie
DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Short term Dermal DNEL Short term Olo DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Olo DNEL Short term Olo DNEL Short term Olo DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Olo DNEL Short term Olo DNEL Long term Olo DNEL Long term Olo DNEL Short term Olo DNEL Long term Dermal DNEL Short term Dermal DNEL DNEL DNEL Short term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL	z-aminoemanoi	DINEL		o. io mg/m³		Systemic
Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Dnemal   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Demal   DNEL   Cong term   Inhalation   DNEL   Cong term   Dermal   Cong term   Doublet   Cong term						
Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Dnemal   Inhalation   DNEL   Long term   Inhalation   DNEL   Short term   Demal   DNEL   Cong term   Inhalation   DNEL   Cong term   Dermal   Cong term   Doublet   Cong term		DNEL	Long term	0.28 mg/m <sup>3</sup>	General	Local
DNEL Long term Inhalation DNEL Long term Oral Long term Oral Long term Oral Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term 10 mg/m³ Inhalation DNEL Long term Inhalation DNEL Long term 10 mg/m³ Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Ones Inhalation DNEL Short term Dermal DNEL Long term Ones Inhalation DNEL Short term Oral DNEL Long term Ones Inhalation DNEL Short term Ones Inhalation DNEL Long term Ones Inhalation DNEL Long term Ones Inhalation DNEL Short term Oral DNEL Long term Ones Inhalation DNEL Long term Ones Inhalation DNEL Long term Ones Inhalation DNEL Short term Ones Inhalation DNEL Long term Ones Inhalation DNEL Short term Ones Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Short term Ones Inhalation DNEL Short term Dermal Inhalation In						
Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Dremal   Long term   Dremal   DNEL   Long term   Dermal   DNEL   Long term   Dermal   DNEL   Long term   Dermal   DNEL   Long term   Dremal   DNEL   Long term   Dnemal   DNEL   Long term   DNEL   Long term   Dnemal   DNEL   Dnemal   Dnem		DNEI		$0.51 \text{ mg/m}^3$		Local
DNEL Long term Oral Long term Oral Long term Dermal DNEL Long term 10 mg/m³ population DNEL Long term 168 mg/m³ population DNEL Long term 168 mg/m³ population DNEL Long term 168 mg/m³ population DNEL Long term DNEL Long term DNEL DNG term DNG DNG DNG Term DNG DNG DNG Term DNG Term DNG DNG Term DNG Tengal DNG Term DNG Tengal DNG Term DNG Tengal DNG Term DNG Tengal		DIVLL		0.51 1119/111	WOINGIS	Local
DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term   Dnemal   DNEL   Dnemal		D. 151				
DNEL Dong term Dermal DNEL Long term Dnemal DNEL Dnemator DNEM		DNEL		1 mg/m³	Workers	Systemic
DNEL Long term Dermal bw/day b			Inhalation			
DNEL Long term Dermal bw/day b		DNEL	Long term Oral	1.5 ma/ka	General	Systemic
DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Oral DNEL Short term Dermal DNEL Short term DNEL Short term DNEL Long term Inhalation DNEL Short term DNEL Short term DNEL Long term Inhalation DNEL Long term DNEL Short term DNEL Short term DNEL Short term DNEL Long term Inhalation DNEL Short term DNEL Short term DNEL Long term DNEL Short term DNEL Sh						- ,
Propylene glycol  DNEL Long term Dermal bw/day 3 mg/kg bw/day 10 mg/m³ lnhalation DNEL Long term Inhalation DNEL Long term Oral Short term DNEL Short term Oral DNEL Long term Onel DNEL Short term Onel DNEL Long term Inhalation DNEL Short term Oral DNEL Long term Onel DNEL Short term Onel DNEL Long term Onel DNEL Long term Onel DNEL Long term Onel DNEL Short term Oral DNEL Long term Onel DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term DNEL Short		חאורו	Long torm Dormal			Cyctomic
Propylene glycol  DNEL Long term   10 mg/m³   10 mg/m³		DINEL	Long term Dermai			Systemic
Propylene glycol  DNEL Long term Inhalation DNEL Long term 10 mg/m³ Workers Local Inhalation DNEL Long term 50 mg/m³ General population Under term Inhalation DNEL Long term 168 mg/m³ Workers Systemic Inhalation DNEL Long term 0.0031 mg/ kg bw/day DNEL Long term 0.0046 mg/ Inhalation DNEL Short term Dermal DNEL Short term Once tend Inhalation DNEL Short term Oral 0.02 mg/ kg bw/day DNEL Short term 0.02 mg/m³ General population General Systemic population Workers Systemic Population General Systemic population Workers Systemic Population General Systemic Population Once						
Propylene glycol  DNEL   Long term   Inhalation   DNEL   Long term   O.0031 mg/ kg bw/day   DNEL   Long term   O.0046 mg/ Inhalation   DNEL   Short term   DNEL   Short term   DNEL   Short term   DNEL   Long term   O.059 mg/ Inhalation   DNEL   Short term   DNEL   Short term   O.02 mg/ kg bw/day   DNEL   Long term   O.02 mg/m²   General   Systemic   population   Systemic   population   Systemic   population   Systemic   population   General   Systemic   population   Systemic   population   General   Systemic   population   Systemic   population   Systemic   population   Short term   O.02 mg/m²   General   Systemic   population   Short term   O.04 mg/m²   General   Systemic   population   Short term   O.04 mg/m²   General   Systemic   population   Systemic   population   Systemic   population   O.16 mg/ kg bw/day   O.43 mg/ kg bw/day   O.43 mg/ kg bw/day   DNEL   Short term   Dermal   Complete   Systemic   Sy		DNEL	Long term Dermal	3 mg/kg	Workers	Systemic
Propylene glycol  DNEL   Long term   Inhalation   DNEL   Long term   O.0031 mg/ kg bw/day   DNEL   Long term   O.0046 mg/ Inhalation   DNEL   Short term   DNEL   Short term   DNEL   Short term   DNEL   Long term   O.059 mg/ Inhalation   DNEL   Short term   DNEL   Short term   O.02 mg/ kg bw/day   DNEL   Long term   O.02 mg/m²   General   Systemic   population   Systemic   population   Systemic   population   Systemic   population   General   Systemic   population   Systemic   population   General   Systemic   population   Systemic   population   Systemic   population   Short term   O.02 mg/m²   General   Systemic   population   Short term   O.04 mg/m²   General   Systemic   population   Short term   O.04 mg/m²   General   Systemic   population   Systemic   population   Systemic   population   O.16 mg/ kg bw/day   O.43 mg/ kg bw/day   O.43 mg/ kg bw/day   DNEL   Short term   Dermal   Complete   Systemic   Sy						
Inhalation   Long term   10 mg/m³   population   Workers   Local	Propylene glycol	DNEI	Long term		Ceneral	Local
DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Long term Onal Inhalation DNEL Short term Dermal DNEL Short term Onal Inhalation DNEL Short term Onal DNEL Long term Onal DNEL Long term Onal DNEL Short term Dermal Inhalation DNEL Short term Onal DNEL Long term Onal DNEL Long term Onal DNEL Long term Onal DNEL Long term Onal Inhalation DNEL Long term Onal Inhalation DNEL Short term Onal Onal Markets Systemic DNEL Inhalation DNEL Long term Onal Inhalation DNEL Short term Onal Onal Markets Systemic DNEL Inhalation DNEL Long term Onal Inhalation DNEL Short term Onal Onal Markets Systemic DNEL Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal Southeast DNEL Short term Dermal DNEL Short term Dermal Southeast DNEL Short term Dermal DNEL Short term Dermal Southeast DNEL Short term D	1 Topyletic grycol	DIVLL		10 1119/111		Local
Inhalation   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   O.0046 mg/ Inhalation   DNEL   Short term   DOMEL   Short term   O.02 mg/ Inhalation   DNEL   Short term   O.02 mg/ Inhalation   DNEL   Cong term   O.04 mg/m³   O.04 m		D. 151		40 / 3		
DNEL Long term Inhalation DNEL Long term Oral  DNEL Short term Dermal  DNEL Long term Oral  DNEL Short term Dermal  DNEL Long term Oral  DNEL Short term Dermal  DNEL Long term Oral  DNEL Long term Dermal  DNEL Derman Der		DNEL		10 mg/m <sup>3</sup>	Workers	Local
Inhalation Long term Inhalation DNEL Dibutyltindilaurate  DNEL DNEL Long term Oral DNEL Long term 0.0031 mg/kg bw/day Inhalation DNEL Short term Dermal DNEL DNEL Short term Oral DNEL Long term 0.05 mg/kg bw/day DNEL Short term Oral DNEL Short term Oral DNEL Short term O.02 mg/kg bw/day DNEL Short term 0.04 mg/m³ Inhalation DNEL Short term 0.04 mg/m³ Inhalation DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL			Inhalation			
Inhalation		DNEL	Long term	50 ma/m³	General	Systemic
DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Short term Oral DNEL Long term Oral DNEL Long term Oral DNEL Short term Oral DNEL Long term Oral DNEL Short term Oral DNEL Long term Oral DNEL Short term Oral DNEL Long term Oral DNEL Short term Oral DNEL Short term Oral DNEL Long term Dermal DNEL Short term DNEL Short t				J.		,
Dibutyltindilaurate  DNEL Long term Oral  DNEL Long term DNEL Short term Dermal DNEL Short term Oral  DNEL Long term Ones Ones Ones Ones Ones Ones Ones Ones		DNE		168 ma/m <sup>3</sup>		Systemic
Dibutyltindilaurate  DNEL Long term Oral 0.0031 mg/kg bw/day 0.0046 mg/ Inhalation m³ 0.059 mg/Inhalation DNEL Short term Dermal DNEL Short term Oral 0.02 mg/kg bw/day DNEL Long term 0.02 mg/kg bw/day DNEL Long term 0.02 mg/kg bw/day DNEL Short term Dermal DNEL Short term 0.02 mg/m³ General population Systemic population General population Systemic population General population Systemic population General population General population Systemic population O.02 mg/kg bw/day population O.02 mg/m³ General population Systemic DNEL Short term 0.04 mg/m³ General population DNEL Short term Dermal 0.16 mg/kg bw/day population ONEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal Systemic Sys		DINEL		100 mg/m	WOINGIS	Cysternic
DNEL Long term   DNEL Short term Oral   DNEL Short term   DNEL Short term   DNEL Short term   DNEL Short term   DNEL Short term Oral   DNEL Short term   DNEL Short term Oral   DNEL Short term   DNEL Short term Dermal   DNEL Short term Dermal   DNEL Short term Dermal Systemic   DNEL Systemic   DNEL Short term Dermal Systemic   DNEL Sho						
DNEL Long term Inhalation DNEL Short term Dermal DNEL Cong term Inhalation DNEL Cong term Dermal Cong term Cong term Dermal Cong t	Dibutyltindilaurate	DNEL	Long term Oral			Systemic
DNEL Long term Inhalation DNEL Short term Dermal DNEL Cong term Inhalation DNEL Cong term Dermal				kg bw/day	population	
Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Dermal   DNEL   Short term   O.059 mg/m   Workers   Systemic   Systemic   DNEL   Short term   O.02 mg/kg   DNEL   Long term   Inhalation   DNEL   Short term   O.02 mg/m   Workers   Systemic   Systemic   DNEL   Short term   O.02 mg/m   Workers   Systemic   Systemic   Systemic   O.02 mg/m   Workers   Systemic   Systemic   Systemic   O.04 mg/m   General   Systemic   DNEL   Long term   O.16 mg/kg bw/day   DNEL   Long term   O.43 mg/kg bw/day   DNEL   Short term   O.43 mg/kg bw/day   DNEL   Short term   O.08 mg/   Workers   Systemic   S		DNEL	Long term			Systemic
DNEL Short term Inhalation DNEL Short term Dermal DNEL Short term Oral DNEL Short term Oral DNEL Long term Inhalation DNEL Short term Dermal DNEL Short term Oral DNEL Short term One Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term DN		<b></b>		0		,
Inhalation DNEL Short term Dermal  DNEL Short term Oral  DNEL Long term Inhalation DNEL Short term  DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal		ראבי				Cyptomia
DNEL Short term Dermal bw/day bw/day 0.02 mg/ kg bw/day 0.02 mg/ kg bw/day population DNEL Long term Inhalation DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal Systemic		DINEL			vvoikers	Systemic
DNEL Short term Oral bw/day 0.02 mg/ kg bw/day population DNEL Long term 1						
DNEL Short term Oral bw/day 0.02 mg/ kg bw/day population DNEL Long term 0.02 mg/m3 Workers Systemic DNEL Short term 0.04 mg/m³ General population DNEL Short term 0.04 mg/m³ General population DNEL Long term Dermal 0.16 mg/ kg bw/day DNEL Long term Dermal 0.43 mg/ kg bw/day DNEL Short term Dermal 2.08 mg/ Workers Systemic		DNEL	Short term Dermal	0.5 mg/kg	General	Systemic
DNEL Long term Inhalation DNEL Short term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal					population	_
DNEL Long term Inhalation  DNEL Short term Dermal  DNEL Long term Dermal  DNEL Long term Dermal  DNEL Short term Dermal  DNEL Long term Dermal  DNEL Short term Dermal  DNEL Short term Dermal  DNEL Short term Dermal  Systemic  Systemic  Systemic  Systemic  Systemic  Systemic  Workers  Systemic  Systemic  Systemic  Workers  Systemic  Systemic  Systemic  Systemic  Systemic  Workers  Systemic		DNEI	Short term Oral			Systemic
DNEL Long term Inhalation  DNEL Short term Inhalation  DNEL Long term Dermal  DNEL Long term Dermal  DNEL Long term Dermal  DNEL Short term Dermal		DINEL	Short tollil Olai			Systemio
Inhalation DNEL Short term   0.04 mg/m³   General population   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Short te		רייבי	1 4			C 4
DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Short term DNEL Short		DNFL		U.02 mg/m <sup>3</sup>	vvorkers	Systemic
Inhalation Long term Dermal  DNEL  Long term Dermal  DNEL  Long term Dermal  DNEL  Short term Dermal  Long term Dermal  DNEL  Systemic  population  General population  Workers  Systemic  Systemic  Workers  Systemic			Inhalation			
Inhalation Long term Dermal  DNEL  Long term Dermal  DNEL  Long term Dermal  DNEL  Short term Dermal  Long term Dermal  DNEL  Systemic  population  General population  Workers  Systemic  Systemic  Workers  Systemic		DNEL	Short term	0.04 mg/m <sup>3</sup>	General	Systemic
DNEL Long term Dermal 0.16 mg/ kg bw/day population  DNEL Long term Dermal 0.43 mg/ Workers Systemic  DNEL Short term Dermal 2.08 mg/ Workers Systemic				3		1
DNEL   Long term Dermal   kg bw/day   population   Systemic		DNE		0.16 mal		Systemia
DNEL Long term Dermal 0.43 mg/ Workers Systemic  DNEL Short term Dermal 2.08 mg/ Workers Systemic  Systemic		DINCL	Long term Dermal			Systernic
DNEL Short term Dermal 2.08 mg/ Workers Systemic						
DNEL Short term Dermal 2.08 mg/ Workers Systemic		DNEL	Long term Dermal	0.43 mg/	Workers	Systemic
DNEL Short term Dermal 2.08 mg/ Workers Systemic			_			_
		DNFI	Short term Dermal		Workers	Systemic
kg bw/day		D. 1LL	Chort tolli Dollilai			2,01011110
				ng bw/day		

**PNECs** 

No PNECs available

: 19/09/2022 Date of issue/Date of revision : 01/12/2023 Date of previous issue **Version** : 1.01 **8/18 Label No** :**7**4790

### SECTION 8: Exposure controls/personal protection

#### 8.2 Exposure controls

Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### Individual protection measures

**Hygiene measures** 

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** 

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists. gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

#### **Skin protection**

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Recommendations: Wear suitable gloves tested to EN374.

> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm Not recommended polyvinyl alcohol (PVA) gloves

**Body protection** 

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** 

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type (spray application):

**Environmental exposure** controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Label No : 74790

### SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

#### **Appearance**

**Physical state** : Liquid. Colour : Grev. Odour Slight

Not available. **Odour threshold** Melting point/freezing point Not available. Initial boiling point and

boiling range

Date of issue/Date of revision : 01/12/2023 · 19/09/2022 Version : 1.01 9/18 Date of previous issue

### **SECTION 9: Physical and chemical properties**

Ingredient name	°C	°F	Method
water	100	212	
2-Propanol, 1-(2-butoxy-1-methylethoxy)	230	446	

Flammability (solid, gas) : Not available.

Upper/lower flammability or explosive limitsLower: Not applicable.Upper: Not applicable.

Flash point :

	Closed cup				Open cu	ıp
Ingredient name	°C	°F	Method	°C	°F	Method
Propanol, 1-(2-butoxy- 1-methylethoxy)	100.4	212.7	ISO 1523			

Auto-ignition temperature

Ingredient name	°C	°F	Method
Propanol, 1-(2-butoxy-1-methylethoxy)	194	381.2	EU A.15

**Decomposition temperature**: Not available.

**PH** : **8** to 8.8 [Conc. (% w/w): 100%]

Viscosity : Not available.

Solubility(ies) :

Not available.

Solubility in water : Not available.

Partition coefficient: n-octanol/ : Not applicable.

water

Vapour pressure :

	V	Vapour Pressure at 20°C			Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
<mark>w</mark> ater	17.5	2.3					
2-Propanol, 1-(2-butoxy- 1-methylethoxy)	0.045	0.006					

Relative density : Not available.

Density : 1.2 g/cm³

Vapour density : Not available.

Explosive properties : Not available.

Oxidising properties : Not available.

**Particle characteristics** 

10.3 Possibility of

Median particle size : Not applicable.

### **SECTION 10: Stability and reactivity**

**10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.

**10.2 Chemical stability** : The product is stable.

hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

**Label No** : **7**4790

10.4 Conditions to avoid : No specific data.

10.5 Incompatible materials : No specific data.

Date of issue/Date of revision: 01/12/2023Date of previous issue: 19/09/2022Version: 1.0110/18

### **SECTION 10: Stability and reactivity**

10.6 Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

### **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

#### **Acute toxicity**

Product/ingredient name	Result	Species	Dose	Exposure
<b>E</b> thanediol	LD50 Oral	Rat	4700 mg/kg	-
Ammonia	LD50 Oral	Rat	350 mg/kg	-
reaction mass of: 5-chloro-	LD50 Oral	Rat	53 mg/kg	-
2-methyl-4-isothiazolin-				
3-one [EC no. 247-500-7]				
and 2-methyl-2H-isothiazol-				
3-one [EC no. 220-239-6] (3:				
1)				
2-methyl-2H-isothiazol-	LC50 Inhalation Dusts and	Rat	0.11 mg/l	4 hours
3-one	mists			
2-aminoethanol	LD50 Oral	Rat	1720 mg/kg	-
Propylene glycol	LD50 Dermal	Rabbit	20800 mg/kg	-
	LD50 Oral	Rat	20 g/kg	-
Dibutyltindilaurate	LD50 Oral	Rat	175 mg/kg	-

### **Conclusion/Summary**

: Based on available data, the classification criteria are not met.

#### **Acute toxicity estimates**

Route	ATE value
Not available.	

#### **Irritation/Corrosion**

Product/ingredient name	Result	Species	Score	Exposure	Observation
titanium dioxide	Skin - Mild irritant	Human	-	72 hours 300	-
				ug I	
2,4,7,9-tetramethyl-5-decyne-4,7-diol	Eyes - Severe irritant	Rabbit	-	0.1 MI	-
	Skin - Mild irritant	Rabbit	-	0.5 g	-
Dipropyleneglycolmethylether	Eyes - Mild irritant	Human	-	8 mg	-
	Eyes - Mild irritant	Rabbit	-	24 hours 500 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
Ethanediol	Eyes - Mild irritant	Rabbit	-	1 hours 100	-
	Eyes - Mild irritant	Rabbit		mg 24 hours 500	_
	Lyos Willa II Italia	rabbit		mg	
	Eyes - Moderate irritant	Rabbit	-	6 hours 1440	-
	Skin - Mild irritant	Rabbit	_	mg 555 mg	_
2-Butoxyethanol	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
	Francisco imitant	Dalahi.		mg	
	Eyes - Severe irritant	Rabbit	-	100 mg	-
Ammonia	Skin - Mild irritant	Rabbit	-	500 mg	-
Ammonia	Eyes - Severe irritant	Rabbit	-	0.5 minutes 1 mg	-
	Eyes - Severe irritant	Rabbit	-	250 ug	-
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and	Skin - Severe irritant	Human	-	0.01 %	-
2-methyl-2H-isothiazol-3-one					
[EC no. 220-239-6] (3:1) 2-aminoethanol	Eyes - Severe irritant	Rabbit	_	250 ug	_
2-aminoethanoi	Skin - Moderate irritant	Rabbit	<u>-</u>	505 mg	_
Propylene glycol	Eyes - Mild irritant	Rabbit	<u>-</u>	100 mg	_
l ropylonio gryoor	Eyes - Mild irritant	Rabbit	_	24 hours 500	_
				mg	

Date of issue/Date of revision : 01/12/2023 Date of previous issue : 19/09/2022 Version : 1.01 11/18

**Label No** : **7**4790

### **SECTION 11: Toxicological information**

	Skin - Mild irritant	Human	-	168 hours	-
				500 mg	
	Skin - Mild irritant	Woman	-	96 hours 30	-
				%	
	Skin - Moderate irritant	Child	-	96 hours 30	-
				% C	
	Skin - Moderate irritant	Human	-	72 hours 104	-
				mg l	
Dibutyltindilaurate	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
				mg	
	Skin - Severe irritant	Rabbit	-	500 mg	-

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

**Sensitisation** 

**Conclusion/Summary** : May cause an allergic skin reaction.

**Mutagenicity** 

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Carcinogenicity

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Reproductive toxicity

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

**Teratogenicity** 

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Ammonia	Category 3		Respiratory tract irritation
2-aminoethanol	Category 3	-	Respiratory tract irritation
Dibutyltindilaurate	Category 1	-	-

### Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
	Category 2 Category 1	oral -	-

#### **Aspiration hazard**

Not available.

Information on likely routes : Not available.

of exposure

Potential acute health effects

**Eye contact** : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards.

: May cause an allergic skin reaction. **Skin contact** 

Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

: No specific data. **Eye contact** Inhalation : No specific data.

**Skin contact** : Adverse symptoms may include the following:

> irritation redness

Date of issue/Date of revision : 01/12/2023 Date of previous issue · 19/09/2022 Version : 1.01 12/18

**Label No** : **7**4790

### **SECTION 11: Toxicological information**

Ingestion : No specific data.

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

**Potential immediate** 

: Not available.

effects

**Potential delayed effects** : Not available.

**Long term exposure** 

**Potential immediate** 

: Not available.

effects

**Potential delayed effects** : Not available.

Potential chronic health effects

Not available.

**Conclusion/Summary** : Not available.

**General** : Once sensitized, a severe allergic reaction may occur when subsequently exposed

to very low levels.

Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards.

Other information : Not available.

### **SECTION 12: Ecological information**

#### 12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
titanium dioxide	Acute LC50 3 mg/l Fresh water	Crustaceans - Water flea - Ceriodaphnia dubia - Neonate	48 hours
	Acute LC50 6.5 mg/l Fresh water	Daphnia - Water flea - <i>Daphnia</i> pulex - Neonate	48 hours
	Acute LC50 >1000000 μg/l Marine water	Fish - Mummichog - Fundulus heteroclitus	96 hours
2,4,7,9-tetramethyl- 5-decyne-4,7-diol	EC50 91 mg/l	Daphnia - <i>Daphnia magna</i>	48 hours
	LC50 42 mg/l	Fish - Cyprinus carpio	96 hours
Ethanediol	Acute LC50 6900000 μg/l Fresh water	Crustaceans - Water flea - Ceriodaphnia dubia - Neonate	48 hours
	Acute LC50 41000000 μg/l Fresh water	Daphnia - Water flea - <i>Daphnia</i> magna - Neonate	48 hours
	Acute LC50 8050000 μg/l Fresh water	Fish - Fathead minnow - Pimephales promelas	96 hours
2-Butoxyethanol	Acute EC50 >1000 mg/l Fresh water	Daphnia - Water flea - <i>Daphnia</i> magna	48 hours
	Acute LC50 800000 μg/l Marine water	Crustaceans - Common shrimp, sand shrimp - Crangon crangon	48 hours
	Acute LC50 1250000 μg/l Marine water	Fish - Inland silverside -  Menidia beryllina	96 hours
Ammonia	Acute LC50 37 ppm Fresh water	Fish - Western mosquitofish - Gambusia affinis - Adult	96 hours
2-methyl-2H-isothiazol-3-one	Acute EC50 0.18 ppm Fresh water	Daphnia - Water flea - <i>Daphnia</i> magna	48 hours
	Acute LC50 0.07 ppm Fresh water	Fish - Rainbow trout,donaldson trout - <i>Oncorhynchus mykiss</i>	96 hours
2-aminoethanol	Acute EC50 8.42 mg/l Fresh water	Algae - Green algae - Desmodesmus subspicatus	72 hours
	Acute LC50 >100000 μg/l Marine water	Crustaceans - Common shrimp, sand shrimp - <i>Crangon crangon</i> - Adult	48 hours
	Acute LC50 170 mg/l Fresh water	Fish - Goldfish - Carassius	96 hours

Date of issue/Date of revision : 01/12/2023 Date of previous issue : 19/09/2022 Version : 1.01 13/18 **Label No** :74790

### **SECTION 12: Ecological information**

		auratus	
Propylene glycol	Acute EC50 19300 mg/l Fresh water	Algae - Algae	96 hours
	Acute EC50 43500 mg/l Fresh water	Daphnia - Daphnia - <i>Daphnia</i>	48 hours
		magna	
	Acute LC50 18340000 µg/l Fresh water	Crustaceans - Water flea -	48 hours
		Ceriodaphnia dubia	
	Acute LC50 40613 mg/l Fresh water	Fish - Trout - Oncorhynchus	96 hours
		mykiss	
Dibutyltindilaurate	Chronic EC10 >2 mg/l Fresh water	Algae - Green algae -	96 hours
		Scenedesmus subspicatus	

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

#### 12.2 Persistence and degradability

**Conclusion/Summary** : This product has not been tested for biodegradation.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
Propylene glycol	-	-	Readily

#### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
<b>D</b> ipropyleneglycolmethylether	0.004	-	Low
Ethanediol	-1.36	-	Low
2-Butoxyethanol	0.81	-	Low
2-aminoethanol	-1.31	-	Low
Propylene glycol	-1.07	-	Low
Dibutyltindilaurate	4.44	2.91	Low

#### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

**Mobility** : Not available.

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

**Hazardous waste** 

The classification of the product may meet the criteria for a hazardous waste.

**European waste** catalogue (EWC) : 080112, 200128

**Packaging** 

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Date of issue/Date of revision : 01/12/2023 Date of previous issue · 19/09/2022 Version : 1.01 14/18 **Label No** : **7**4790

### SECTION 13: Disposal considerations

**Special precautions** 

: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

### **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	IATA
14.1 UN number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not relevant/applicable due to nature of the product.

### SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture **UK (GB)/REACH** 

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Substances of very high concern

None of the components are listed.

Ozone depleting substances

Not listed.

**Prior Informed Consent (PIC)** 

Not listed.

**Persistent Organic Pollutants** 

Not listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

No listed substance

**Seveso Directive** 

This product is not controlled under the Seveso Directive.

**EU regulations** 

Date of issue/Date of revision : 01/12/2023 · 19/09/2022 Version : 1.01 15/18 Date of previous issue

Label No : 74790

### **SECTION 15: Regulatory information**

Industrial emissions : Not listed (integrated pollution

prevention and control) -

Air

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Water

**International regulations** 

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

**Montreal Protocol** 

Not listed.

**Stockholm Convention on Persistent Organic Pollutants** 

Not listed.

**Rotterdam Convention on Prior Informed Consent (PIC)** 

Not listed.

**UNECE Aarhus Protocol on POPs and Heavy Metals** 

Not listed.

15.2 Chemical safety

assessment

: This product contains substances for which Chemical Safety Assessments are still

required.

#### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

: ATE = Acute Toxicity Estimate

GB CLP = UK CLP (EC No 1272/2008) on the Classification, Labelling and

Packaging of Substances and Mixtures as amended by (EU Exit) Regulations 2019

**Label No** : **7**4790

No. 720 and amendments

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = GB CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification

Classification	Justification
Skin Sens. 1, H317	Calculation method

#### Full text of abbreviated H statements

<b>⊮</b> 301	Toxic if swallowed.
H302	Harmful if swallowed.
H310	Fatal in contact with skin.
H311	Toxic in contact with skin.
H312	Harmful in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.

Date of issue/Date of revision : 01/12/2023 Date of previous issue : 19/09/2022 Version : 1.01 16/18

### **SECTION 16: Other information**

H341	Suspected of causing genetic defects.
H351	Suspected of causing cancer.
H360	May damage fertility or the unborn child.
H370	Causes damage to organs.
H372	Causes damage to organs through prolonged or repeated exposure.
H373	May cause damage to organs through prolonged or repeated exposure.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH071	Corrosive to the respiratory tract.

#### Full text of classifications

Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 3	ACUTE TOXICITY - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Carc. 2	CARCINOGENICITY - Category 2
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Muta. 2	GERM CELL MUTAGENICITY - Category 2
Repr. 1B	REPRODUCTIVE TOXICITY - Category 1B
Skin Corr. 1B	SKIN CORROSION/IRRITATION - Category 1B
Skin Corr. 1C	SKIN CORROSION/IRRITATION - Category 1C
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
Skin Sens. 1B	SKIN SENSITISATION - Category 1B
STOT RE 1	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2
STOT SE 1	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 1
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3
Data of Consul Data of	04/40/0000

Date of issue/ Date of : 01/12/2023

revision

Date of previous issue : 19/09/2022

**Version** : 1.01

#### **Notice to reader**

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision : 01/12/2023 Date of previous issue : 19/09/2022 Version : 1.01 17/18 **Label No** : **7**4790

Date of issue/Date of revision Version : 1.01 18/18 : 01/12/2023 Date of previous issue : 19/09/2022 **Label No** :**7**4790